{"id":11403730,"date":"2026-07-15T06:41:25","date_gmt":"2026-07-15T03:41:25","guid":{"rendered":"https:\/\/nostylelike.net\/?post_type=product&#038;p=11403730"},"modified":"2026-08-27T14:20:58","modified_gmt":"2026-08-27T11:20:58","slug":"pyzchiva-45-mg-ustekinumab","status":"publish","type":"product","link":"https:\/\/nostylelike.net\/en\/product\/pyzchiva-45-mg-ustekinumab\/","title":{"rendered":"Pyzchiva 45 mg Ustekinumab Biosimilar Pre-filled Syringe"},"content":{"rendered":"<figure><img decoding=\"async\" src=\"https:\/\/nostylelike.net\/wp-content\/uploads\/2026\/07\/pyzchiva-45mg-ustekinumab-product-display.webp\" alt=\"Pyzchiva 45 mg\" loading=\"lazy\"\/><\/figure>\n<p><strong>Pyzchiva 45 mg<\/strong> is available at No Style Like. Below you will find full details on its benefits, uses, dosage, and important precautions.<\/p>\n<div dir=\"ltr\" style=\"text-align: left;\">\n<h2 id=\"top\">Pyzchiva 45 mg (Ustekinumab Biosimilar) Pre-filled Syringe \u2014 Complete Guide for Psoriasis and Inflammatory Bowel Disease<\/h2>\n<div style=\"background: #f5f0fa; border-left: 4px solid #5b2d90; padding: 16px; border-radius: 8px;\">\n<p><strong>Quick Answer:<\/strong> Pyzchiva 45 mg is a biosimilar to ustekinumab (Stelara), used to treat moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn&#8217;s disease, and ulcerative colitis in adults, and plaque psoriasis and psoriatic arthritis in children 6 years and older. It works by blocking interleukin-12 and interleukin-23 (IL-12\/23). After starting doses at week 0 and week 4, maintenance is typically every 12 weeks, under specialist supervision.<\/p>\n<\/div>\n<h2 id=\"key-facts\">Key Facts Table<\/h2>\n<table>\n<tbody>\n<tr>\n<th>Item<\/th>\n<th>Details<\/th>\n<\/tr>\n<tr>\n<td>Active ingredient<\/td>\n<td>Ustekinumab (biosimilar to originator ustekinumab)<\/td>\n<\/tr>\n<tr>\n<td>Strength<\/td>\n<td>45 mg \/ 0.5 mL pre-filled syringe (90 mg also available for higher body weight)<\/td>\n<\/tr>\n<tr>\n<td>Drug class<\/td>\n<td>Biosimilar \u2014 IL-12 and IL-23 inhibitor<\/td>\n<\/tr>\n<tr>\n<td>Main uses<\/td>\n<td>Plaque psoriasis, psoriatic arthritis, Crohn&#8217;s disease, ulcerative colitis<\/td>\n<\/tr>\n<tr>\n<td>Dosing (psoriasis\/PsA)<\/td>\n<td>45 mg (or 90 mg if &gt;100 kg) at week 0 and week 4, then every 12 weeks<\/td>\n<\/tr>\n<tr>\n<td>Route<\/td>\n<td>Subcutaneous injection (initial IV option for Crohn&#8217;s\/UC induction)<\/td>\n<\/tr>\n<tr>\n<td>Prescription status<\/td>\n<td>Prescription only \u2014 specialist supervision<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 id=\"short-desc\">Short Description<\/h2>\n<p>Pyzchiva is a biosimilar version of ustekinumab that blocks IL-12 and IL-23, two cytokines central to the inflammation behind psoriasis, psoriatic arthritis, and inflammatory bowel disease. It offers the same clinical benefit as the reference biologic, confirmed through extensive comparability studies, with a notably infrequent every-12-week maintenance schedule.<\/p>\n<h2 id=\"toc\">Table of Contents<\/h2>\n<ul>\n<li><a href=\"#intro\">Introduction<\/a><\/li>\n<li><a href=\"#what-is\">What Is Pyzchiva?<\/a><\/li>\n<li><a href=\"#how-works\">How Does It Work?<\/a><\/li>\n<li><a href=\"#benefits\">Main Benefits<\/a><\/li>\n<li><a href=\"#use-cases\">Real Use Cases<\/a><\/li>\n<li><a href=\"#best-for\">Who Is It Best For?<\/a><\/li>\n<li><a href=\"#avoid\">Who Should Avoid It?<\/a><\/li>\n<li><a href=\"#how-to-use\">How to Use Correctly<\/a><\/li>\n<li><a href=\"#best-time\">Best Time to Use<\/a><\/li>\n<li><a href=\"#common-questions\">Common Questions Users Ask<\/a><\/li>\n<li><a href=\"#results-timeline\">Expected Results Timeline<\/a><\/li>\n<li><a href=\"#mistakes\">Common Mistakes<\/a><\/li>\n<li><a href=\"#myths\">Myths vs Facts<\/a><\/li>\n<li><a href=\"#interactions\">Drug Interactions<\/a><\/li>\n<li><a href=\"#contraindications\">Contraindications<\/a><\/li>\n<li><a href=\"#tests\">Required Tests<\/a><\/li>\n<li><a href=\"#nutrition\">What to Eat With It<\/a><\/li>\n<li><a href=\"#other-meds\">Effect on Other Medications<\/a><\/li>\n<li><a href=\"#see-doctor\">When To See a Doctor<\/a><\/li>\n<li><a href=\"#expert-tip\">NSL Expert Tip<\/a><\/li>\n<li><a href=\"#faq\">Conversational FAQ<\/a><\/li>\n<li><a href=\"#conclusion\">Conclusion<\/a><\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"intro\">Introduction<\/h2>\n<p>Ustekinumab was a landmark biologic when introduced, targeting IL-12 and IL-23 rather than the more commonly blocked TNF-alpha pathway, and it remains a mainstay across psoriasis, psoriatic arthritis, and inflammatory bowel disease. Pyzchiva brings this well-established therapy to more patients as a biosimilar, backed by phase III comparability data showing equivalent skin-clearance outcomes to the reference product.<\/p>\n<hr \/>\n<h2 id=\"what-is\">What Is Pyzchiva?<\/h2>\n<p>Pyzchiva is a biosimilar medicinal product containing ustekinumab, a human monoclonal antibody. It is approved for adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately-to-severely active Crohn&#8217;s disease, and moderately-to-severely active ulcerative colitis, as well as children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis.<\/p>\n<hr \/>\n<h2 id=\"how-works\">How Does It Work?<\/h2>\n<p>Ustekinumab binds to the shared p40 subunit of interleukin-12 (IL-12) and interleukin-23 (IL-23), preventing these cytokines from binding to their receptors on immune cells. Both IL-12 and IL-23 play a role in activating T cells that drive inflammation in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Blocking both simultaneously interrupts this inflammatory signaling, reducing skin plaques, joint symptoms, and intestinal inflammation.<\/p>\n<hr \/>\n<h2 id=\"benefits\">Main Benefits<\/h2>\n<ul>\n<li>Same proven mechanism and efficacy as originator ustekinumab, confirmed through biosimilarity studies (comparable PASI score improvements).<\/li>\n<li>Notably infrequent maintenance dosing \u2014 every 12 weeks for psoriasis and psoriatic arthritis after the starting doses.<\/li>\n<li>Approved across a wide range of conditions: skin, joints, and inflammatory bowel disease.<\/li>\n<li>Pediatric indication available for plaque psoriasis and psoriatic arthritis (6 years and older).<\/li>\n<li>Weight-based dosing options ensure appropriate coverage for larger body weights.<\/li>\n<li>Self-injectable at home after training, using a pre-filled syringe or autoinjector.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"use-cases\">Real Use Cases<\/h2>\n<ul>\n<li>An adult with moderate-to-severe plaque psoriasis seeking a therapy with infrequent dosing.<\/li>\n<li>A psoriatic arthritis patient needing systemic biologic control of joint and skin symptoms.<\/li>\n<li>A Crohn&#8217;s disease or ulcerative colitis patient with inadequate response to conventional therapy.<\/li>\n<li>A child or adolescent (6+) with moderate-to-severe plaque psoriasis or psoriatic arthritis.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"best-for\">Who Is It Best For?<\/h2>\n<p>Adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately-to-severely active Crohn&#8217;s disease, or ulcerative colitis, and children 6 years and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis, under specialist care (dermatology, rheumatology, or gastroenterology depending on indication).<\/p>\n<hr \/>\n<h2 id=\"avoid\">Who Should Avoid It?<\/h2>\n<ul>\n<li>Anyone with hypersensitivity to ustekinumab or excipients.<\/li>\n<li>Patients with clinically significant active infections until resolved.<\/li>\n<li>Patients with untreated latent tuberculosis until prophylaxis is initiated \u2014 TB screening is required before starting.<\/li>\n<li>Report any history of noninfectious pneumonia symptoms (interstitial, eosinophilic, or cryptogenic organizing pneumonia have been reported with ustekinumab products).<\/li>\n<li>Caution regarding live vaccines, which should be completed before starting treatment.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"how-to-use\">How to Use Correctly<\/h2>\n<ol>\n<li><strong>Plaque psoriasis \/ psoriatic arthritis (\u2264100 kg):<\/strong> 45 mg subcutaneously at week 0, then again at week 4, then every 12 weeks.<\/li>\n<li><strong>Plaque psoriasis (&gt;100 kg):<\/strong> 90 mg using the same schedule.<\/li>\n<li><strong>Crohn&#8217;s disease \/ ulcerative colitis:<\/strong> a weight-based intravenous induction dose, followed by 90 mg subcutaneously 8 weeks later, then every 8 weeks.<\/li>\n<li><strong>Pediatric dosing:<\/strong> weight-based at the initial dose, 4 weeks later, then every 12 weeks.<\/li>\n<li>Inject into the thigh, abdomen, upper arm, or buttock; rotate sites and avoid psoriasis plaques or damaged skin.<\/li>\n<li>Let the syringe reach room temperature before injecting, per the leaflet.<\/li>\n<\/ol>\n<hr \/>\n<h2 id=\"best-time\">Best Time to Use<\/h2>\n<p>Follow the two starting doses precisely (week 0 and week 4), then settle into your maintenance interval (every 8 or 12 weeks depending on condition) on a fixed calendar date. Because the interval is long, marking future injection dates well in advance helps avoid missed doses.<\/p>\n<hr \/>\n<h2 id=\"common-questions\">Common Questions Users Ask<\/h2>\n<p><strong>Why does dosing depend on body weight for psoriasis but not for IBD?<\/strong> Psoriasis and psoriatic arthritis dosing uses a fixed 45 mg or 90 mg based on a 100 kg weight threshold, while Crohn&#8217;s disease and ulcerative colitis induction dosing is calculated more precisely based on actual body weight.<\/p>\n<p><strong>Is a biosimilar as effective as ustekinumab?<\/strong> Yes \u2014 Pyzchiva&#8217;s phase III trial showed comparable improvement in psoriasis severity scores to the reference product, confirming biosimilarity.<\/p>\n<p><strong>How often will I need injections long-term?<\/strong> For psoriasis and psoriatic arthritis, typically every 12 weeks \u2014 one of the least frequent dosing schedules among biologics.<\/p>\n<hr \/>\n<h2 id=\"results-timeline\">Expected Results Timeline<\/h2>\n<table>\n<tbody>\n<tr>\n<th>Period<\/th>\n<th>What to Expect<\/th>\n<\/tr>\n<tr>\n<td>4 weeks<\/td>\n<td>Second starting dose given; early improvement possible in some patients.<\/td>\n<\/tr>\n<tr>\n<td>12\u201316 weeks<\/td>\n<td>Formal assessment; meaningful skin, joint, or bowel symptom improvement typically evident.<\/td>\n<\/tr>\n<tr>\n<td>Ongoing<\/td>\n<td>Maintenance dosing (every 8 or 12 weeks depending on condition) sustains the response.<\/td>\n<\/tr>\n<tr>\n<td>Long term<\/td>\n<td>Continued monitoring for infection risk and overall disease control.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"mistakes\">Common Mistakes<\/h2>\n<ul>\n<li>Missing the second starting dose at week 4, which is essential for establishing full effect.<\/li>\n<li>Confusing the psoriasis\/PsA dosing interval (every 12 weeks) with the IBD interval (every 8 weeks).<\/li>\n<li>Losing track of the long maintenance interval and missing scheduled doses.<\/li>\n<li>Assuming a biosimilar is less effective than the reference biologic despite equivalent trial data.<\/li>\n<li>Not completing TB screening or vaccinations before starting.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"myths\">Myths vs Facts<\/h2>\n<table>\n<tbody>\n<tr>\n<th>Myth<\/th>\n<th>Fact<\/th>\n<\/tr>\n<tr>\n<td>&#8220;Biosimilars have weaker effects than the original biologic.&#8221;<\/td>\n<td>Pyzchiva&#8217;s phase III trial demonstrated comparable psoriasis severity score improvement to reference ustekinumab.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;All my conditions use the same dosing schedule.&#8221;<\/td>\n<td>Psoriasis and psoriatic arthritis typically use every-12-week maintenance, while Crohn&#8217;s disease and ulcerative colitis use every-8-week maintenance after IV induction.<\/td>\n<\/tr>\n<tr>\n<td>&#8220;Since dosing is infrequent, missing one dose doesn&#8217;t matter much.&#8221;<\/td>\n<td>Missing doses in a long-interval schedule can allow disease activity to return; consistency remains important despite the infrequent schedule.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<hr \/>\n<h2 id=\"interactions\">Drug Interactions<\/h2>\n<ul>\n<li><strong>Live vaccines:<\/strong> avoid during treatment; complete vaccinations beforehand.<\/li>\n<li><strong>Other biologics or strong immunosuppressants:<\/strong> combination is generally avoided due to increased infection risk.<\/li>\n<li>Report all medications to your specialist, particularly any other systemic therapies for the same condition.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"contraindications\">Contraindications<\/h2>\n<p>Hypersensitivity to ustekinumab or any excipient. Clinically significant active infections should be resolved before starting, and untreated latent tuberculosis requires prophylaxis first.<\/p>\n<hr \/>\n<h2 id=\"tests\">Required Tests<\/h2>\n<ul>\n<li>Tuberculosis screening before starting.<\/li>\n<li>Review and completion of age-appropriate vaccinations prior to treatment.<\/li>\n<li>Ongoing clinical assessment of skin, joint, or bowel symptom response.<\/li>\n<li>Monitoring for respiratory symptoms given reports of noninfectious pneumonia with ustekinumab products.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"nutrition\">What to Eat With It<\/h2>\n<p>Pyzchiva has no specific food interactions. A balanced, anti-inflammatory-leaning diet \u2014 rich in vegetables, whole grains, omega-3 sources, and adequate protein \u2014 supports overall skin and joint health during treatment. Patients with Crohn&#8217;s disease or ulcerative colitis should follow specific dietary guidance from their gastroenterologist, since nutritional needs can differ significantly during flares versus remission.<\/p>\n<hr \/>\n<h2 id=\"other-meds\">Effect on Other Medications<\/h2>\n<p>As a biologic antibody, ustekinumab does not act through liver enzyme pathways the way small-molecule drugs typically do. The main practical considerations are vaccine timing and avoiding combination with other immunosuppressive biologics unless specifically directed by your specialist.<\/p>\n<hr \/>\n<h2 id=\"see-doctor\">When To See a Doctor<\/h2>\n<ul>\n<li>Signs of infection: persistent fever, cough, or any severe or unusual infection.<\/li>\n<li>New or worsening respiratory symptoms such as shortness of breath or persistent cough, given reports of noninfectious pneumonia.<\/li>\n<li>Allergic reaction symptoms: swelling, hives, difficulty breathing.<\/li>\n<li>No meaningful improvement by the expected assessment point (around week 12\u201316).<\/li>\n<li>Before any planned vaccination or surgery.<\/li>\n<\/ul>\n<hr \/>\n<h2 id=\"expert-tip\">NSL Expert Tip<\/h2>\n<div style=\"background: #fdf2f7; border: 1px solid #d63384; padding: 14px; border-radius: 8px;\">\n<p><strong>Dr. Abdallah Fouad \u2014 Clinical Nutrition Specialist:<\/strong> Don&#8217;t underestimate how easy it is to lose track of a 12-week interval \u2014 mark your next several injection dates on a calendar as soon as your specialist confirms your schedule. And don&#8217;t let the word &#8220;biosimilar&#8221; create hesitation; Pyzchiva&#8217;s trial data showed comparable results to the original ustekinumab across the key measures that matter for psoriasis severity.<\/p>\n<\/div>\n<hr \/>\n<h2 id=\"faq\">Conversational FAQ<\/h2>\n<p><strong>Is Pyzchiva the same as Stelara?<\/strong><br \/>\nPyzchiva is a biosimilar to originator ustekinumab (Stelara), containing the same active substance with demonstrated equivalent efficacy and safety in regulatory trials.<\/p>\n<p><strong>How is my dose determined for psoriasis?<\/strong><br \/>\nBody weight determines whether you receive 45 mg or 90 mg \u2014 patients over 100 kg typically receive the higher dose.<\/p>\n<p><strong>Can children use Pyzchiva?<\/strong><br \/>\nYes, it is approved for moderate-to-severe plaque psoriasis and active psoriatic arthritis in children 6 years and older, with weight-based dosing.<\/p>\n<p><strong>Why is the IBD schedule different from the psoriasis schedule?<\/strong><br \/>\nCrohn&#8217;s disease and ulcerative colitis begin with a weight-based intravenous induction dose, then switch to subcutaneous maintenance every 8 weeks, reflecting the specific dosing studied for these conditions.<\/p>\n<p><strong>Do I need TB screening?<\/strong><br \/>\nYes, tuberculosis screening is standard before starting Pyzchiva, as with other biologics targeting the immune system.<\/p>\n<hr \/>\n<h2 id=\"conclusion\">Conclusion<\/h2>\n<p>Pyzchiva 45 mg offers the well-established benefits of ustekinumab therapy \u2014 blocking both IL-12 and IL-23 across plaque psoriasis, psoriatic arthritis, Crohn&#8217;s disease, and ulcerative colitis \u2014 through a biosimilar with comparable efficacy confirmed in clinical trials. With correct condition-specific dosing, appropriate pre-treatment screening, and attention to the long maintenance interval, it provides a reliable and notably infrequent-dosing option across this range of inflammatory conditions. It remains a prescription-only biologic requiring specialist supervision.<\/p>\n<div style=\"background: #f8f9fa; border: 1px solid #dee2e6; padding: 12px; border-radius: 8px; font-size: 0.9em;\">\n<p><strong>Medically reviewed by:<\/strong> Dr. Abdallah Fouad \u2014 Clinical Nutrition Specialist, 25+ years of clinical experience.<\/p>\n<p><strong>Medical Disclaimer:<\/strong> This content is educational and not a substitute for professional medical advice. Pyzchiva is a prescription-only biosimilar biologic requiring specialist supervision and pre-treatment screening. Sources: European Medicines Agency (EMA) and U.S. FDA product information for Pyzchiva (ustekinumab).<\/p>\n<\/div>\n<\/div>\n<h2>Related Products &#038; Useful Resources<\/h2>\n<p>You may also like related products such as <a href=\"https:\/\/nostylelike.net\/en\/product\/buy-panadol-cold-flu-24-caplets-fast-relief-for-cold-flu-symptoms\/\">Buy Panadol Cold &#038; Flu 24 Caplets \u2013<\/a> , <a href=\"https:\/\/nostylelike.net\/en\/product\/panadol-extra-24-tablets-fast-pain\/\">Panadol Extra 24 Tablets<\/a> from our store.<\/p>\n<p>For more trusted medical information, refer to <a href=\"https:\/\/www.drugs.com\/\" target=\"_blank\" rel=\"noopener nofollow\">Drugs.com<\/a>. Always consult your doctor or pharmacist before use.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pyzchiva 45 mg is an ustekinumab biosimilar (IL-12\/23 inhibitor) for plaque psoriasis, psoriatic arthritis, Crohn\u2019s disease and ulcerative colitis, with infrequent every-12-week maintenance. Prescription only.<\/p>\n","protected":false},"featured_media":11405498,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[42048,41601],"product_tag":[],"class_list":["post-11403730","product","type-product","status-publish","has-post-thumbnail","product_cat-anti-inflammatory","product_cat-autoimmune-disease-treatments","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/comments?post=11403730"}],"version-history":[{"count":3,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403730\/revisions"}],"predecessor-version":[{"id":11405924,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product\/11403730\/revisions\/11405924"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media\/11405498"}],"wp:attachment":[{"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/media?parent=11403730"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_brand?post=11403730"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_cat?post=11403730"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/nostylelike.net\/en\/wp-json\/wp\/v2\/product_tag?post=11403730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}